Fibrosing interstitial lung disease - A drug from the specified list Factor
Last reviewed for CCPS 16 December 2009.
Investigative Documents
Medical Report - Treatment with a Specified Drug [MR9422]
Preliminary questions [40670]
there is some evidence that being treated with a drug from the specified list for fibrosing interstitial lung disease may be a factor in the development or worsening of the condition under consideration.40947 the veteran has been treated with a drug from the specified list for fibrosing interstitial lung disease at some time.
the veteran was treated with a drug from the specified list for fibrosing interstitial lung disease for treatment of an illness or injury which is identifiable.40951 — the veteran has established the causal connection between treatment with a drug from the specified list and VEA service for fibrosing interstitial lung disease.
for treatment of the identified illness or injury, the veteran was treated with a drug from the specified list for fibrosing interstitial lung disease within the six months before the clinical onset of fibrosing interstitial lung disease.40952 — the veteran has established the causal connection between treatment with a drug from the specified list and VEA service for the clinical onset of fibrosing interstitial lung disease.
40954 — the veteran has established the causal connection between treatment with a drug from the specified list and operational service for the clinical onset of fibrosing interstitial lung disease.
or
40955 — the veteran has established the causal connection between treatment with a drug from the specified list and eligible service for the clinical onset of fibrosing interstitial lung disease.
or
the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service. the condition under consideration permanently worsened. for treatment of the identified illness or injury, the veteran was treated with a drug from the specified list for fibrosing interstitial lung disease within the six months before the clinical worsening of fibrosing interstitial lung disease.40953 — the veteran has established the causal connection between treatment with a drug from the specified list and VEA service for the clinical worsening of fibrosing interstitial lung disease.
40956 — the veteran has established the causal connection between treatment with a drug from the specified list and operational service for the clinical worsening of fibrosing interstitial lung disease.
or
40957 — the veteran has established the causal connection between treatment with a drug from the specified list and eligible service for the clinical worsening of fibrosing interstitial lung disease.
Clinical onset and operational service [40954]
40958 — the identified illness or injury, for which the veteran was treated with a drug from the specified list for fibrosing interstitial lung disease, is causally related to operational service.
Clinical onset and eligible service [40955]
40959 — the identified illness or injury, for which the veteran was treated with a drug from the specified list for fibrosing interstitial lung disease, is causally related to eligible service.
Clinical worsening and operational service [40956]
40958 — the identified illness or injury, for which the veteran was treated with a drug from the specified list for fibrosing interstitial lung disease, is causally related to operational service.
the clinical onset of the condition under consideration occurred prior to that part of operational service to which the identified illness or injury, for which the veteran was treated with a drug from the specified list for fibrosing interstitial lung disease, is causally related.Clinical worsening and eligible service [40957]
40959 — the identified illness or injury, for which the veteran was treated with a drug from the specified list for fibrosing interstitial lung disease, is causally related to eligible service.
the clinical onset of the condition under consideration occurred prior to that part of eligible service to which the identified illness or injury, for which the veteran was treated with a drug from the specified list for fibrosing interstitial lung disease, is causally related.